Amylyx Pharmaceuticals (AMLX) Long-Term Debt Issuances (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) posted quarterly Long-Term Debt Issuances of -$375000.0 for Q4 2025, down 100.2% quarter-over-quarter from $191.1 million in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Long-Term Debt Issuances (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$375000.0 for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$375000.0; the TTM figure through Dec 2025 stood at $256.3 million (changed N/A YoY), while the FY2025 annual figure was $256.3 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at -$375000.0, down from $191.1 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $191.1 million in Q3 2025, with the low at -$375000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -375,000.00 |
| Dec 31, 2025 | -375,000.00 |
| Sep 30, 2025 | 191.11 Mn |
| Sep 30, 2025 | 191.11 Mn |
| Mar 31, 2025 | 65.58 Mn |
| Mar 31, 2025 | 65.58 Mn |
| Mar 31, 2021 | 11.89 Mn |
| Mar 31, 2021 | 11.89 Mn |